Comparison of pSS and SS/RA
| pSS | SS/RA | P value | |
| Number of patients | 124 | 62 | |
| Female sex (n,%) | 112/124 (90%) | 49/62 (79%) | 0.033 |
| Age | 55.06(13,9) | 53.55(14,3) | 0.539 |
| Disease duration | 8.8 years(8.8) | 8.1 years (8.8) | |
| Tobacco | 19/112 (17%) | 16/55 (29%) | 0.07 |
| Asthenia (n, %) | 99/122 (81%) | 35/41 (85%) | 0.541 |
| Dry eye (n, %) | 107/124 (86%) | 47/56 (84%) | 0.676 |
| Dry mouth (n, %) | 111/124 (89%) | 48/55 (87%) | 0.660 |
| Others sicca syndrome (vagina and skin) (n, %) | 90/118 (76%) | 30/51 (58%) | 0.022 |
| Parotid enlargement (n, %) | 61/123 (49.6%) | 13/59 (22%) | <0001 |
| Myositis (n, %) | 1/123 (1%) | 1/60 (2%) | 0.602 |
| Arthralgia (n, %) | 61/108 (56.5%) | 54/62 (87%) | <0001 |
| Arthritis (n, %) | 20/123 (16.3%) | 57/62 (92%) | <0001 |
| Peripheral neurological involvement (n, %) | 10/121 (8.3%) | 1/62 (1.6%) | 0.073 |
| Central neurological involvement (n, %) | 2/123 (1.6%) | 0/62 (0%) | 0.313 |
| Pulmonary involvement (n, %) | 7/123 (5.7%) | 9/62 (14.5%) | 0.044 |
| Renal involvement (n, %) | 3/123 (2.4%) | 0/61 (0%) | 0.219 |
| Lymphadenopathy, (n, %) | 15/123 (12.2%) | 7/62 (11.3%) | 0.858 |
| Lymphoma (n, %) | 9/123 (7%) | 2/62 (3%) | 0.267 |
| IgG levels (g/L)(Mean (SD)) | 13.6 (6.6)/113 | 15 (4.7)/45 | 0.067 |
| Presence of monoclonal peak (n, %) | 10/114 (9%) | 7/55 (13%) | 0.423 |
| CRP (mg/L)(Mean (SD)) | 6.3 (6.5)/112 | 13.6 (23.4)/61 | 0.184 |
| ESR (mm at 1 hour)(Mean (SD)) | 23.6 (21)/109 | 39.7 (27.3)/58 | <0001 |
| Lymphocytes count (/mm3)(Mean (SD)) | 1673 (1212)/118 | 1657(636)/62 | 0.494 |
| Beta2-microglobulin (mg/L)(Mean (SD)) | 2.3 (1.1)/101 | 2.7 (1.5)/39 | 0.172 |
| LDH (U/L)(Mean (SD)) | 344 (101)/105 | 350 (57.9)/37 | 0.344 |
| C3 (g/L)(Mean (SD)) | 1.09 (0.3)/111 | 1.1 (0.3)/43 | 0.893 |
| C4 (g/L)(Mean (SD)) | 0.31 (0.9)/111 | 0.22 (0.1)/42 | 0.987 |
| Anti-SSA antibodies (n, %) | 86/120 (72%) | 35/60 (58%) | 0.072 |
| Anti-SSB antibodies (n, %) | 48/122 (39%) | 17/58 (29%) | 0.19 |
| RF positivity (n, %) | 57/119 (48%) | 54/62 (87%) | <0001 |
| RF levels when detectable (UI/mL)(Mean (SD)) | 426(794) | 348(569) | 0.651 |
| Anti-CCP (n, %) | 1/107 (1%) | 55/62 (89%) | <0001 |
| Cryoglobulinemia (n, %) | 2/123 (2%) | 3/62 (5%) | 0.203 |
| ESSDAI | 3.745 | 6.3 (5.5) | <0001 |
| Cumulative ESSDAI | 6.8 (7,5) | 9.2 (5.7) | <0001 |
| ESSDAI without joint domain | 2.85 (4.8) | 3.2 (4.8) | 0.971 |
| Cumulative ESSDAI without joint domain | 5.4 (7.4) | 4.5 (5.3) | 0.573 |
Variables are presented as mean (SD) or number and percentage.